Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Head to Head Analysis: Cardiff Oncology (NASDAQ:CRDF) and BioStem Technologies (OTCMKTS:BSEM)
04:26am, Wednesday, 11'th Mar 2026
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast t
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus Target Price from Analysts
01:10am, Thursday, 05'th Mar 2026
Cardiff Oncology, Inc. (NASDAQ: CRDF - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat Ratings reports. One
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
04:01pm, Thursday, 26'th Feb 2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
05:05am, Thursday, 26'th Feb 2026
Cardiff Oncology (NASDAQ: CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly s
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
04:30pm, Tuesday, 24'th Feb 2026
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:00am, Thursday, 19'th Feb 2026
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Average Target Price from Brokerages
01:10am, Sunday, 08'th Feb 2026
Shares of Cardiff Oncology, Inc. (NASDAQ: CRDF - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One
Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus
06:23am, Wednesday, 28'th Jan 2026
Cardiff Oncology Inc. (NASDAQ: CRDF) on Tuesday closed around 32% lower after the management update and trial update.
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
02:12am, Wednesday, 28'th Jan 2026
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
07:05am, Tuesday, 27'th Jan 2026
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in pa
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
07:00am, Tuesday, 27'th Jan 2026
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages
02:16am, Wednesday, 14'th Jan 2026
Shares of Cardiff Oncology, Inc. (NASDAQ: CRDF - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the firm, MarketBeat
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm
10:48am, Tuesday, 13'th Jan 2026
Cardiff Oncology (CRDF) remains a single-asset biotech, with its thesis reliant on onvansertib targeting PLK1 in difficult-to-treat cancers. Recent phase 2 CRDF-004 data showed diminished response rat
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference
07:00am, Monday, 08'th Dec 2025
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
